Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Dec 28;10(1):40.
doi: 10.1186/s40246-016-0096-9.

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma

Kuang-Leei Chang  1 , Ming-Yung Lee  2 , Wan-Ru Chao  3 , Chih-Ping Han  4   5
Affiliations
Comment

The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma

Kuang-Leei Chang et al. Hum Genomics. .

Abstract

Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutant-enriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese patients were examined to determine the status of Her2 amplification and Kras mutations. Our results showed the Her2 amplification rates were 33.33%, while the Kras mutation rates were 61.90%. We present here our results in order to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report another 2 novel Kras mutations (A11V, V14I).

Keywords: Her2 amplification; Kras mutation; Mucinous ovarian carcinoma.

PubMed Disclaimer

Comment on

  • Ovarian cancer.
    Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Jayson GC, et al. Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21. Lancet. 2014. PMID: 24767708 Review.

References

    1. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376–88. doi: 10.1016/S0140-6736(13)62146-7. - DOI - PubMed
    1. Chao WR, Lee MY, Lin WL, Koo CL, Sheu GT, Han CP. Assessing the HER2 status in mucinous epithelial ovarian cancer on the basis of the 2013 ASCO/CAP guideline update. Am J Surg Pathol. 2014;38:1227–34. doi: 10.1097/PAS.0000000000000268. - DOI - PubMed
    1. Li XS, Sun J, He XL. Expression of c-myc and mutation of the Kras gene in patients with ovarian mucinous tumors. Genet Mol Res. 2015;14:10752–9. doi: 10.4238/2015.September.9.14. - DOI - PubMed
    1. Auner V, Kriegshäuser G, Tong D, et al. Kras mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer. 2009;9:111. doi: 10.1186/1471-2407-9-111. - DOI - PMC - PubMed
    1. Perren TJ. Mucinous epithelial ovarian carcinoma. Ann Oncol. 2016;27(suppl 1):i53–7. doi: 10.1093/annonc/mdw087. - DOI - PubMed

Substances